

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number
WO 01/17553 A1

(51) International Patent Classification⁷: A61K 39/245,
39/27, C12N 7/00, 7/06

(21) International Application Number: PCT/EP00/08944

(22) International Filing Date:
11 September 2000 (11.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99202933.0 10 September 1999 (10.09.1999) EP

(71) Applicant (for all designated States except US): AKZO
NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Am-
hem (NL).

(72) Inventor; and

(75) Inventor/Applicant (for US only): PATEL, Jay, R.
[GB/GB]; Highfield Cottage, 51 Westdrive, Caldecote,
Cambridge CB3 7NY (GB).

(74) Agent: OGILVIE-EMANUELSON, C., M.; P.O. Box 20,
NL-5340 BH Oss (NL).

(81) Designated States (national): AE, AG, AL, AU, BA, BB,
BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE,
HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV,
MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG,
SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.
- With (an) indication(s) in relation to deposited biological
material furnished under Rule 13bis separately from the
description.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 01/17553 A1

(54) Title: EQUINE HERPES VIRUS TEMPERATURE SENSITIVE MUTANT AND LIVE VACCINE THEREOF

(57) Abstract: The present invention relates to an equine abortion virus (EHV-1) mutant which is temperature sensitive at the body temperature of the host animal, more specifically at a temperature of 38.5 °C or higher. The temperature sensitive mutant can be used in vaccination to protect susceptible animals against EHV-1 infection. The invention furthermore relates to live vaccines derived from said mutant.